SeaStar Medical Schedules Q2 Earnings Amid Critical Trial Progress
Event summary
- SeaStar Medical will report Q2 financial results on August 12, 2026.
- The company's first commercial product, QUELIMMUNE (SCD-PED), was FDA-approved in 2024 for pediatric AKI due to sepsis.
- SeaStar is conducting the NEUTRALIZE-AKI pivotal trial for adult AKI patients.
- The SCD therapy has received Breakthrough Device Designation for six indications.
The big picture
SeaStar Medical is navigating a critical phase with its FDA-approved product and ongoing pivotal trial, positioning itself at the forefront of treatments for life-threatening organ failure conditions. The company's strategic focus on rare and severe indications could drive significant market differentiation if clinical and commercial milestones are met.
What we're watching
- Regulatory Momentum
- Whether the Breakthrough Device Designation will accelerate approval timelines for additional indications.
- Trial Execution
- The pace at which the NEUTRALIZE-AKI trial progresses and its potential impact on adult AKI treatment options.
- Commercialization Strategy
- How SeaStar Medical plans to scale QUELIMMUNE's market penetration in the ultra-rare pediatric AKI segment.
Related topics